Spnib 50mg Tablet

Spnib 50 mg Tablet contains Dasatinib 50 mg, a targeted anticancer medicine belonging to the tyrosine kinase inhibitor (TKI) class. It is primarily used to treat Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML) in chronic, accelerated, or blast phases, and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) in adults and certain children, as prescribed by an oncologist. Dasatinib works by blocking abnormal proteins that stimulate the uncontrolled growth of cancer cells, thereby slowing or stopping the progression of leukemia. It is often prescribed when patients do not respond to or cannot tolerate other treatments such as imatinib. Treatment requires regular monitoring of blood counts, liver function, and heart health because serious side effects may occur. Spnib should be taken exactly as prescribed and only under the supervision of a cancer specialist.

Spnib 50 mg Tablet contains Dasatinib, a second-generation tyrosine kinase inhibitor (TKI) used to treat Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL). The Philadelphia chromosome produces an abnormal BCR-ABL tyrosine kinase, which continuously signals leukemia cells to grow and divide uncontrollably. Dasatinib blocks this abnormal enzyme along with several other tyrosine kinases involved in cancer cell survival, effectively slowing or stopping leukemia progression. This targeted mechanism helps destroy abnormal blood cells while minimizing damage to healthy tissues compared with traditional chemotherapy.

Dasatinib is particularly valuable for patients who are resistant to or intolerant of earlier therapies such as imatinib. Regular monitoring of blood counts, liver function, and cardiovascular health is essential because treatment may cause bone marrow suppression, bleeding, infections, or fluid accumulation around the lungs. Consistent use under specialist supervision improves long-term disease control and treatment outcomes.

Precaution

• Regular blood tests are required to monitor blood cell counts and liver function.
• Inform your doctor if you have liver disease, heart disease, bleeding disorders, or lung disease.
• Dasatinib may increase the risk of infections and bleeding.
• Avoid live vaccines during treatment unless approved by your doctor.
• Use effective contraception during treatment and for the recommended period afterward, as Dasatinib may harm an unborn baby.
• Inform your doctor about all medicines you take, including antacids and herbal supplements, as drug interactions are common.

Storage

• Store below 30°C in a cool, dry place.
• Protect from moisture and direct sunlight.
• Keep the tablets in the original packaging.
• Keep out of reach of children.
• Do not use after the expiry date.